º£½ÇÉçÇøappUrges FDA to Affirm Role of Clinical Labs for COVID-19 Serology Testing
On April 21, 2020, º£½ÇÉçÇøappsubmitted the following letter to the Food and Drug Administration (FDA) acknowledging the need for adoption of serology testing conducted in a way that ensures both reliability and accuracy​.
Dear Commissioner Hahn:
On behalf of the º£½ÇÉçÇøapp, which includes thousands of public health and clinical laboratory microbiologists, we appreciate the FDA’s willingness to maintain an open dialogue with our leadership and members as the COVID-19 pandemic continues. As we look to the next phase of addressing the impact of the virus, º£½ÇÉçÇøapprecognizes the need for widespread adoption of serology, or antibody testing, to put our nation back on a path of public and economic health. In order to do that, antibody tests need to be accurate, reliable and provide meaningful information.
With major health and economic policy decisions hanging in the balance as the U.S. seeks to get a handle on the effects of the COVID-19 pandemic, it is imperative that these tests are effective and conducted in a way that ensures both reliability and accuracy.
We urge FDA to clarify its current guidance that serology tests that have not received Emergency Use Authorization (EUA) must be conducted in CLIA or CAP-certified high complexity labs. This policy ensures that appropriate validation has been done before testing begins.
We are concerned that uncertainty around the current guidance may result in non-EUA tests being performed outside these tightly controlled environments. FDA must use its oversight authority to prevent unauthorized testing from taking place.
In March, we acknowledged the steps you took to streamline the regulatory process to enable the pursuit of antibody tests given they can inform doctors and public health officials about a person’s exposure to and potential immunity to the virus. We support the FDA’s current position that the only tests allowed to voluntarily submit to the EUA process are those that are to be conducted in CLIA-certified or CAP-certified high complexity laboratories. We appreciate FDA’s recognition that testing in these settings is overseen by highly trained, board-certified doctoral-level directors of clinical laboratories that follow strict procedures for validating tests for accuracy and reliability before offering them to patients and/or the public.
We also appreciate the invitation for our members to share validation information with the FDA as they bring these tests online in their labs, and we encourage FDA to provide validation information conducted in federal agency-led post-market reviews back to the clinical microbiologists. Having a two-way communication channel will allow a more rapid exchange of valuable information and allow all parties to work more efficiently and effectively. Any system devised by the FDA for collecting this data from our members should allow for confidentiality and if possible, anonymity.
We recognize that this continues to be a complex and evolving situation. º£½ÇÉçÇøapplooks forward to working with you to ensure millions of Americans will have greater access to antibody tests at this critical juncture in the pandemic, and that these tests are accurate and reliable.
Sincerely,
Robin Patel, M.D.
President
Stefano Bertuzzi, Ph.D.
Chief Executive Officer
Melissa Miller, Ph.D.
Chair, º£½ÇÉçÇøappClinical and Public Health Microbiology Committee
Dear Commissioner Hahn:
On behalf of the º£½ÇÉçÇøapp, which includes thousands of public health and clinical laboratory microbiologists, we appreciate the FDA’s willingness to maintain an open dialogue with our leadership and members as the COVID-19 pandemic continues. As we look to the next phase of addressing the impact of the virus, º£½ÇÉçÇøapprecognizes the need for widespread adoption of serology, or antibody testing, to put our nation back on a path of public and economic health. In order to do that, antibody tests need to be accurate, reliable and provide meaningful information.
With major health and economic policy decisions hanging in the balance as the U.S. seeks to get a handle on the effects of the COVID-19 pandemic, it is imperative that these tests are effective and conducted in a way that ensures both reliability and accuracy.
We urge FDA to clarify its current guidance that serology tests that have not received Emergency Use Authorization (EUA) must be conducted in CLIA or CAP-certified high complexity labs. This policy ensures that appropriate validation has been done before testing begins.
We are concerned that uncertainty around the current guidance may result in non-EUA tests being performed outside these tightly controlled environments. FDA must use its oversight authority to prevent unauthorized testing from taking place.
In March, we acknowledged the steps you took to streamline the regulatory process to enable the pursuit of antibody tests given they can inform doctors and public health officials about a person’s exposure to and potential immunity to the virus. We support the FDA’s current position that the only tests allowed to voluntarily submit to the EUA process are those that are to be conducted in CLIA-certified or CAP-certified high complexity laboratories. We appreciate FDA’s recognition that testing in these settings is overseen by highly trained, board-certified doctoral-level directors of clinical laboratories that follow strict procedures for validating tests for accuracy and reliability before offering them to patients and/or the public.
We also appreciate the invitation for our members to share validation information with the FDA as they bring these tests online in their labs, and we encourage FDA to provide validation information conducted in federal agency-led post-market reviews back to the clinical microbiologists. Having a two-way communication channel will allow a more rapid exchange of valuable information and allow all parties to work more efficiently and effectively. Any system devised by the FDA for collecting this data from our members should allow for confidentiality and if possible, anonymity.
We recognize that this continues to be a complex and evolving situation. º£½ÇÉçÇøapplooks forward to working with you to ensure millions of Americans will have greater access to antibody tests at this critical juncture in the pandemic, and that these tests are accurate and reliable.
Sincerely,
Robin Patel, M.D.
President
Stefano Bertuzzi, Ph.D.
Chief Executive Officer
Melissa Miller, Ph.D.
Chair, º£½ÇÉçÇøappClinical and Public Health Microbiology Committee
